Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Immutep (Germany)
h-index: 10
Total citations: 359
Total papers: 32
Homepage:
http://www.immutep.com/
Recent papers from Immutep (Germany)
Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients.
Journal of Clinical Oncology · 2026
Abstract PS1-09-16: Optimal biological dose of eftilagimod alpha, a soluble LAG-3 protein, in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003
Clinical Cancer Research · 2026
Technical-pedagogical usability of digital inclusive reading support evolving through practice-to-research transfer
Frontiers in Education · 2025
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2024
Eftilagimod alpha (soluble LAG-3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma
Clinical Cancer Research · 2024
200P Testing a higher dose (90 mg s.c.) of eftilagimod alpha, a soluble LAG-3 protein in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003
ESMO Open · 2024
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
Clinical Cancer Research · 2023
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology
ESMO Open · 2023
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
Journal for ImmunoTherapy of Cancer · 2020
A LAG-3–Specific Agonist Antibody for the Treatment of T Cell–Induced Autoimmune Diseases
The Journal of Immunology · 2020
Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial
SHILAP Revista de lepidopterología · 2016
Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity
OncoImmunology · 2014
A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer
Journal for ImmunoTherapy of Cancer · 2014